These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
314 related articles for article (PubMed ID: 21348538)
1. Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin. Boulton DW; Li L; Frevert EU; Tang A; Castaneda L; Vachharajani NN; Kornhauser DM; Patel CG Clin Pharmacokinet; 2011 Apr; 50(4):253-65. PubMed ID: 21348538 [TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic study of saxagliptin in healthy Chinese subjects. Li H; Yang L; Tou CK; Patel CG; Zhao J Clin Drug Investig; 2012 Jul; 32(7):465-73. PubMed ID: 22668067 [TBL] [Abstract][Full Text] [Related]
3. Clinical Pharmacokinetics and Pharmacodynamics of Saxagliptin, a Dipeptidyl Peptidase-4 Inhibitor. Boulton DW Clin Pharmacokinet; 2017 Jan; 56(1):11-24. PubMed ID: 27282159 [TBL] [Abstract][Full Text] [Related]
4. Single-dose pharmacokinetic studies of abiraterone acetate in men with hepatic or renal impairment. Marbury T; Lawitz E; Stonerock R; Gonzalez M; Jiao J; Breeding J; Haqq C; Verboven P; Stieltjes H; Yu M; Molina A; Acharya M; Chien C; Tran N J Clin Pharmacol; 2014 Jul; 54(7):732-41. PubMed ID: 24374856 [TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Scheen AJ Diabetes Obes Metab; 2010 Aug; 12(8):648-58. PubMed ID: 20590741 [TBL] [Abstract][Full Text] [Related]
6. Bioequivalence of saxagliptin/metformin extended-release (XR) fixed-dose combination tablets and single-component saxagliptin and metformin XR tablets in healthy adult subjects. Boulton DW; Smith CH; Li L; Huang J; Tang A; LaCreta FP Clin Drug Investig; 2011; 31(9):619-30. PubMed ID: 21819160 [TBL] [Abstract][Full Text] [Related]
7. Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study. Nowicki M; Rychlik I; Haller H; Warren M; Suchower L; Gause-Nilsson I; Schützer KM Int J Clin Pract; 2011 Dec; 65(12):1230-9. PubMed ID: 21977965 [TBL] [Abstract][Full Text] [Related]
8. The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptin. He YL; Sabo R; Campestrini J; Wang Y; Ligueros-Saylan M; Lasseter KC; Dilzer SC; Howard D; Dole WP Eur J Clin Pharmacol; 2007 Jul; 63(7):677-86. PubMed ID: 17486328 [TBL] [Abstract][Full Text] [Related]
9. Saxagliptin plus metformin combination in patients with type 2 diabetes and renal impairment. Scheen AJ Expert Opin Drug Metab Toxicol; 2012 Mar; 8(3):383-94. PubMed ID: 22313172 [TBL] [Abstract][Full Text] [Related]
10. Effect of rifampicin on the pharmacokinetics and pharmacodynamics of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in healthy subjects. Upreti VV; Boulton DW; Li L; Ching A; Su H; Lacreta FP; Patel CG Br J Clin Pharmacol; 2011 Jul; 72(1):92-102. PubMed ID: 21651615 [TBL] [Abstract][Full Text] [Related]
11. Bioequivalence of saxagliptin/metformin immediate release (IR) fixed-dose combination tablets and single-component saxagliptin and metformin IR tablets in healthy adult subjects. Upreti VV; Keung CF; Boulton DW; Chang M; Li L; Tang A; Hsiang BC; Quamina-Edghill D; Frevert EU; Lacreta FP Clin Drug Investig; 2013 May; 33(5):365-74. PubMed ID: 23549864 [TBL] [Abstract][Full Text] [Related]
12. Single-dose pharmacokinetics of boceprevir in subjects with impaired hepatic or renal function. Treitel M; Marbury T; Preston RA; Triantafyllou I; Feely W; O'Mara E; Kasserra C; Gupta S; Hughes EA Clin Pharmacokinet; 2012 Sep; 51(9):619-28. PubMed ID: 22799589 [TBL] [Abstract][Full Text] [Related]
13. Effect of hepatic or renal impairment on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor. Devineni D; Curtin CR; Marbury TC; Smith W; Vaccaro N; Wexler D; Vandebosch A; Rusch S; Stieltjes H; Wajs E Clin Ther; 2015 Mar; 37(3):610-628.e4. PubMed ID: 25659911 [TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics, safety, and tolerability of maraviroc in HIV-negative subjects with impaired renal function. Vourvahis M; Fang J; Checchio T; Milton A; Weatherley B; McFadyen L; Heera J HIV Clin Trials; 2013; 14(3):99-109. PubMed ID: 23835512 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of dalbavancin in patients with renal or hepatic impairment. Marbury T; Dowell JA; Seltzer E; Buckwalter M J Clin Pharmacol; 2009 Apr; 49(4):465-76. PubMed ID: 19318696 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of Voxelotor in Patients With Renal and Hepatic Impairment. Preston RA; Marbury T; Balaratnam G; Green M; Dixon S; Lehrer-Graiwer J; Washington C J Clin Pharmacol; 2021 Apr; 61(4):493-505. PubMed ID: 33084052 [TBL] [Abstract][Full Text] [Related]
17. Phase I trial to investigate the effect of renal impairment on isavuconazole pharmacokinetics. Townsend RW; Akhtar S; Alcorn H; Berg JK; Kowalski DL; Mujais S; Desai AV Eur J Clin Pharmacol; 2017 Jun; 73(6):669-678. PubMed ID: 28271239 [TBL] [Abstract][Full Text] [Related]
18. Saxagliptin: a review of its use as combination therapy in the management of type 2 diabetes mellitus in the EU. Yang LP Drugs; 2012 Jan; 72(2):229-48. PubMed ID: 22221000 [TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of intravenous conivaptan in subjects with hepatic or renal impairment. Roy MJ; Erdman KA; Abeyratne AT; Plumb LC; Lasseter K; Riff DS; Keirns JJ Clin Pharmacokinet; 2013 May; 52(5):385-95. PubMed ID: 23456393 [TBL] [Abstract][Full Text] [Related]
20. Bioequivalence and Food Effect of Dapagliflozin/Saxagliptin/Metformin Extended-release Fixed-combination Drug Products Compared With Coadministration of the Individual Components in Healthy Subjects. Tang W; Engman H; Zhu Y; Dayton B; Boulton DW Clin Ther; 2019 Aug; 41(8):1545-1563. PubMed ID: 31266654 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]